Hemochromatosis or iron overload in simple terms is a disorder in which body accumulates too much iron. This may be genetic or acquired as a result of other disease or treatments such as anemia, thalassemia, liver disease, excessive iron shots or pills or blood transfusions. Genetic Hemochromatosis is the most common type of iron overload disease. In this disease, the human body cannot get rid of excess iron which then begins to accumulate in body tissues and organs such as heart, liver, lungs, and kidneys. People with hemochromatosis absorb up to four times more iron than the normal people.
HEMOCHROMATOSIS THERAPEUTICS UNDER DEVELOPMENT (2018)
Symptoms for severe iron overload are fatigue and weakness, menopause in women, High sugar level, bronze coloration of the skin, weight loss and pain in joints. With time complications such as diabetes and cardiomyopathy may occur.
Currently there are only three iron chelator drugs in the market namely; Deferasirox, Deferoxamine and Deferiprone and cost of treatment is high as well. So, more companies are seeking to come up with the cost-effective treatments for Hemochromatosis.
As of March 2018, the hemochromatosis therapeutics pipeline comprises of nine drug candidates in different stages of development.
Some of the key players involved in the development of Hemochromatosis therapeutics include Shire Plc, Silence Therapeutics Plc and Alnylam Pharmaceuticals Inc.